SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as a report surfaced regarding security flaws in a battlefield communication system, triggering a sharp sell-off despite the company's rebuttal and claims that the issues were resolved. The community is debating the severity and validity of the report, with some viewing it as a buying opportunity while others express concerns about the company's valuation. Discussions also involve the potential impact on government contracts and the trustworthiness of news sources.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amid discussions around Novo Nordisk's potential entry into the telehealth space with an obesity pill, which could impact HIMS' market share, while others are pointing out that weightloss is only a small part of the business. The community is debating whether this news presents a buying opportunity or signals a concerning shift in the competitive landscape, especially since some are looking at the COO exit as a negative catalyst. Some traders are noting technical levels and expressing frustration with the stock's volatile price action and seeming sensitivity to news.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as investors discuss its potential U.S. expansion and speculate on a possible Nasdaq relisting, with community members pointing to strong fundamentals driving the stock. The company's growth in China, coupled with Starbucks' struggles, is fueling optimism, while others remain cautious due to past accounting issues and the stock's OTC status.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as retail investors and traders discuss its impressive recent gains and potential for future growth within the quantum computing sector. Community members are weighing the possibility of a short squeeze against concerns of overvaluation and a potential offering, while some highlight a recent purchase order announcement. The stock's momentum is drawing attention, with debates swirling around its long-term prospects compared to others in the quantum computing space.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation ($ACHR) is trending amid high trading volume and anticipation surrounding potential catalysts, including upcoming airshows and FAA certification progress. The community is actively discussing the possibility of a short squeeze, as well as potential partnerships, with some drawing attention to Tesla's presence in a recent promotional video. Discussions also involve comparisons to sector peer Joby Aviation, with some traders anticipating $ACHR closing the market cap gap.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors debate its AI spending and monetization strategies, highlighted by a recent report on AI chatbots exploring ad revenue. Community chatter reflects concerns about its recent price action, with some viewing it as a buying opportunity while others express bearish sentiment. Broader discussions include Meta's competition in the AI and AR spaces, particularly around its smart glasses.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending due to speculation surrounding potential US government investment, fueled by the CEO's confirmation of White House discussions; the community is debating the significance of these talks and comparing USAR to other rare earth companies like MP Materials and LAC. Some investors are concerned about potential dilution from share unlocks and insider selling, while others remain optimistic about USAR's role in securing a domestic rare earth supply chain amid increasing geopolitical tensions.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending amid speculation of a potential buyout, with community members pointing to increased volume and options activity as possible indicators. Chatter suggests that a big tech company could be interested in acquiring the AI firm to bolster its own AI capabilities. Despite recent financial results and leadership changes, the stock is seeing increased interest.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

CLNN is trending as community members discuss the potential for accelerated approval of its ALS treatment following positive commentary from the FDA. Conversations revolve around the company's cash flow, potential offerings, and the possibility of a data leak driving the recent price movement. Some investors express excitement and relief, while others remain cautious due to past experiences and the need for further positive developments.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience is trending amid community discussion around a potential short squeeze and recent gains. Some traders cite the company's fundamentals, upcoming data readouts, and potential for a large upside. Others remain cautious, pointing to past trial failures and ongoing discussions about a possible offering.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz

Shares of Inozyme Pharma, Inc. (INZY) rocketed 179% on Friday after BioMarin Pharmaceutical (BMRN) agreed to <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.inozyme.com/news-releases/news-release-details/biomarin-strengthens-enzyme-therapy-business-acquisition-inozyme">acquire</a> the company for $270 million.Under the deal, BioMarin will acquire Inozyme for $4 per share in an all-cash transaction. The deal's per-share price consideration implies an 182% premium to Inozyme’s closing price of $1.42 on Thursday.BioMarin will commence a cash tender to acquire all of Inozyme's outstanding shares. A majority of the outstanding shares must be tendered for its consummation.Inozyme's Board of Directors unanimously recommended that shareholders tender their shares in the offer.Following the successful completion of the tender offer, a wholly-owned subsidiary of BioMarin will merge with Inozyme. The transaction is expected to close in the third quarter of 2025.BioMarin said that it expects the acquisition to strengthen its enzyme therapies portfolio.Inozyme’s late-stage enzyme replacement therapy, INZ-701, is currently being assessed for the treatment of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 deficiency (ENPP1), a rare genetic disorder caused by mutations in the ENPP1 gene, leading to loss of ENPP1 enzymatic activity. Currently, there are no approved therapies for ENPP1 Deficiency, Inozyme said.BioMarin CEO Alexander Hardy said that the company will continue to evaluate both external and internal innovation going forward.“We are in a strong financial position to bring in additional assets as we accelerate the development of medicines for patients with significant unmet need," he said.On Stocktwits, retail sentiment around Inozyme jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours while message volume jumped from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_16_at_12_31_33_PM_png_8f9ddbb20d.webp" alt="INZY's Sentiment Meter and Message Volume as of 12:30 p.m. ET on May 16, 2025 | Source: Stocktwits" width="628" height="60"><figcaption>INZY's Sentiment Meter and Message Volume as of 12:30 p.m. ET on May 16, 2025 | Source: Stocktwits</figcaption></figure>For BioMarin, retail sentiment around the company fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours.<figure class="image"><img style="aspect-ratio:626/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_16_at_12_32_33_PM_png_3cde3c49bc.webp" alt="BMRN's Sentiment Meter and Message Volume as of 12:30 p.m. ET on May 16, 2025 | Source: Stocktwits" width="626" height="64"><figcaption>BMRN's Sentiment Meter and Message Volume as of 12:30 p.m. ET on May 16, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/INZY">INZY stock</a> has gained by 39% this year but has fallen by nearly 16% over the past 12 months.<a href="https://stocktwits.com/symbol/BMRN">BMRN stock</a> is trading nearly 2% higher as of Friday noon.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/volkswagen-shareholders-flag-governance-issues-at-car-company/chiwBRDRbnU">Volkswagen Shareholders Flag Governance Issues At Carmaker, Says Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens

The deal's per-share price consideration implies an 182% premium to Inozyme’s closing price of $1.42 on Thursday.

Inozyme Stock Rockets 178% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens

Equity

The deal's per-share price consideration implies an 182% premium to Inozyme’s closing price of $1.42 on Thursday.


Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look'

Stifel initiates coverage on Inozyme Pharma with a Buy rating and a $16 price target, highlighting INZ-701's potential to treat rare diseases like ENPP1 and ABCC6 deficiencies.
read more...

Inozyme Pharma, Inc. (NASDAQ:INZY) CEO Douglas A. Treco Sells 7,523 Shares

Inozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) CEO Douglas A. Treco sold 7,523 shares of the business's stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an...

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) ( Company or Inozyme ), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for...

Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) ( the Company or Inozyme ), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics...

Inozyme Pharma (INZY, $7.3) RSI Indicator left the overbought zone on April 01, 2024

This is a signal that INZY's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Inozyme Pharma (INZY, $7.4) RSI Indicator left the overbought zone on March 27, 2024

Inozyme Pharma (INZY, $6.78) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 26, 2024

This is a Bullish indicator signaling INZY's price could rise from here. Traders may explore going long the stock or buying call options...

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. It engages in the business of developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company was founded by Axel Bolte, Joseph P. Schlessinger, and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.

Inozyme Pharma Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

INZY
Inozyme Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest INZY News

INZY Inozyme Pharma Inc